Benjamin Lockshin, MD, FAAD, the director of the Clinical Trials Center at U.S. Dermatology Partners, discusses using bimekizumab (Bimzelx) for the treatment of moderate-to-severe psoriasis and psoriatic arthritis. In the BE READY trial (NCT03410992), bimekizumab demonstrated the ability to achieve high levels of skin clearance, with 80% mean improvement in 4 weeks and complete clearance in 16 weeks, faster than other biologics.